Search
Berdazimer
go.drugbank.com/drugs/DB18712Approved[A262965] On Jan 05, 2024, the FDA approved berdazimer under the brand name ZELSUVMI for the treatment of adult and pediatric molluscum contagiosum, and it is the first drug to be approved for this … [A262960] Berdazimer was previously investigated as a potential treatment for molluscum contagiosum, a viral cutaneous infection mainly affecting children, sexually active adults, and immunocompromised
Salsalate
go.drugbank.com/drugs/DB01399ApprovedInvestigationalSuch capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours. … Salsalate is a nonsteroidal anti-inflammatory agent for oral administration.
Celiprolol
go.drugbank.com/drugs/DB04846ApprovedInvestigationalWithdrawnCeliprolol is not approved for use by the FDA in the treatment of vascular Ehlers–Danlos syndrome. … Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris.
Insomnia
go.drugbank.com/conditions/DBCOND0017531Drugs: Amitriptyline · Brotizolam · Butabarbital · Cinolazepam · Clotiazepam · Daridorexant +31 moreNeisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen
go.drugbank.com/drugs/DB10801ApprovedInvestigationalNeisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria … The vaccine contains *N. meningitis* serogroup W-135 capsular polysaccharide antigens that are purified and individually conjugated to diphtheria toxoid protein that are extracted from *Corynebacterium
Minocycline
go.drugbank.com/drugs/DB01017ApprovedInvestigationalMinocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifi...
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseDigoxin
go.drugbank.com/drugs/DB00390ApprovedInvestigational[L9143] This drug originates from the foxglove plant, also known as the _Digitalis_ plant[T610], studied by William Withering, an English physician and botanist in the 1780s. … [A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant.
Categories: Compounds used in a research, industrial, or household settingProducts: DIGOXINA POR 0.25MG CAPSULAS BLANDASDanicopan
go.drugbank.com/drugs/DB15401ApprovedInvestigational[A263501,L50417] Both hemolysis and thrombophilia are mediated primarily by the complement system.[A263501] Standard therapy for PNH involves the use of complement C5 inhibitors (e.g. … [L50381] It was first approved in January 2024 in Japan for patients with PNH,[A263506,L50416] shortly after which the EMA adopted a positive opinion and recommended granting it marketing authorization
Pinaverium
go.drugbank.com/drugs/DB09090ApprovedInvestigationalPinaverium is a spasmolytic agent used for functional gastrointestinal disorders. It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function. … Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada.
Categories: Drugs for Functional Gastrointestinal DisordersFaropenem medoxomil
go.drugbank.com/drugs/DB05659InvestigationalThe prodrug form of faropenem offers dramatically improved oral bioavailability and leads to higher systemic concentrations of the drug. … It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc.